Millennium Research Group (MRG; Waltham, Massachusetts) said it has conducted a detailed analysis of the U.S. large-joint implant market. The analysis finds that one of the latest trends in the U.S. knee implant market is the emergence of gender-specific knees, the introduction and promotion of which is expected to drive revenue growth over the next five years. Another trend in the largest segment of the US knee implant market — primary total knee replacement (TKR) — will be the expected launch of additional mobile bearing knees (MBKs). Part of a three-report series covering the U.S., Europe, and Japan markets, Large-Joint Implants 2007 reports that by 2011, the U.S. reconstructive knee implant market will be more than $5 billion.
MRG calls itself the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector.
100 receive PAVR with CoreValve System
CoreValve (Irvine, California) said that a total of 100 patients at nine worldwide investigative sites have now undergone percutaneous aortic valve replacement (PAVR) on a beating heart with the CoreValve Percutaneous ReValving System to treat either their aortic stenosis, aortic regurgitation, or failed-tissue-valve-prosthesis conditions.
“It is important to note that these patients are able to realize a substantially improved quality-of-life at follow-up now out to nearly two years in some cases,” said Jacques Sguin, MD, PhD, chairman, CEO and founder of CoreValve. “The 100th ReValving patient also represents the 21st patient who has undergone the ReValving procedure with our third-generation device, and the ease of implantation of the 18-French delivery catheter is fast-forwarding adoption by the interventionalists who participate in the ongoing clinical trial of ReValving. Because the reduced-size delivery catheter allows access in patients with smaller or more diseased arteries, a much wider range of patients can undergo the ReValving procedure — all high-risk patients who are contraindicated for the only other active-treatment alternative: open-heart surgery.”
CoreValve has developed a delivery system for percutaneous heart valve replacement, based on a novel catheter-and-self-expanding-frame approach on a beating heart.
DiaSys files Form 10-KSB
DiaSys (Waterbury, Connecticut) on Nov. 15 filed its annual report on Form 10-KSB for its fiscal year ended June 30, 2006. Accordingly, the company has satisfied requirements for continued listing of its common stock on the OTC Bulletin Board under the symbol DYXC.OB.
DiaSys makes medical laboratory equipment, consumables and infectious disease test kits.